Insights AI

The market’s most important stocks, simplified

OUTPERFORMING

UNDERPERFORMING

POPULAR TICKERS

AAL AMD AMZN AVGO BA BABA BAC C COIN DAL DIS F HIMS HOOD INTC MARA META MSFT MSTR MU NFLX NIO NKE NVDA OXY PLTR PYPL RIOT RIVN SMCI SNAP SOFI TSLA TSM UBER WFC WOLF

AAPL GOOG GOOGL KO LLY MRNA PFE T UNH VZ WMT XOM

AAL AAPL AMD AMZN AVGO BA BABA BAC C COIN DAL DIS F GOOG GOOGL HIMS HOOD INTC KO LLY MARA META MRNA MSFT MSTR MU NFLX NIO NKE NVDA OXY PFE PLTR PYPL RIOT RIVN SMCI SNAP SOFI T TSLA TSM UBER UNH VZ WFC WMT WOLF XOM

Why is Hims & Hers Health Inc stock outperforming the market?

Hims & Hers Health Inc. demonstrated strong financial and operational performance, with significant revenue and subscriber growth. In Q1 2025, revenue surged 111% year-over-year to $586.01 million, surpassing analyst estimates of $538.2 million, while EPS of $0.20 exceeded expectations of $0.12. Subscriber growth reached 2.4 million, up 38% year-over-year, with a gross margin of 73%, operating cash flow of $109.1 million, and free cash flow of $50.1 million. However, Q2 revenue guidance of $530–$550 million fell short of analyst projections of $564.56 million. For FY 2025, revenue is expected to range between $2.3 billion and $2.4 billion, aligning closely with analyst expectations. The company projects long-term annual revenue of $6.5 billion and adjusted EBITDA of $1.3 billion by 2030, emphasizing its focus on personalized, affordable healthcare. In Q4 2024, revenue grew 69% year-over-year to $481.14 million, exceeding estimates of $470.31 million, with EPS of $0.11 meeting expectations. Subscriber growth reached 2.2 million, up 45% year-over-year, and the gross margin was 77%, slightly below the forecast of 78.4%. The GLP-1 offering contributed over $225 million in annual revenue, though the stock faced pressure after the FDA removed semaglutide injections from the shortage list. Analysts have raised 12-month price targets, with an average of $36.85, reflecting a 32.7% increase, and some targets as high as $68.00. The company’s financial health is robust, with a net margin of 5.41%, ROE of 5.68%, and a debt-to-equity ratio of 0.02, all exceeding industry averages. Despite short-term market volatility, Hims & Hers remains optimistic about its long-term growth trajectory.

Source content provided by Benzinga.
This content was created in whole or in part using Generative Artificial Intelligence (AI). Please read the disclosures found at the end of this content for more information.

Ready to make your move?

You’ve seen the news. It’s time to set your strategy. The TradeStation ecosystem is designed to execute your trades no matter how unique or complex. Set your strategy in motion with the advanced tools and brokerage services built specifically for those who are born to trade

Open account Log in

Recent news for HIMS

News in this section is provided by Benzinga and is written entirely by Benzinga authors. Articles are presented as they were provided by Benzinga, and do not represent the opinions of TradeStation or its employees.

By clicking one of the links below, you are leaving TradeStation.com.

Hims & Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month

Hims & Hers Health shares fell 4.1% Wednesday morning. Despite the pullback, the stock remains up an impressive 116% over the past month.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Hims & Hers Stock Soars 29% On Strong Q1 Earnings, Subscriber Growth

Shares of Hims & Hers have gained 29% over the past week. The move higher has been driven by an impressive Q1 earnings report released last week.

About HIMS

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, ... dermatology, haircare and more. Read more Read less

Ways to trade options* on HIMS

Bullish Option Strategy: Long Calls

Traders buy a single call option on a stock or ETF. This strategy can benefit from a price increase while risking more capital than a spread.

Learn more

Bullish Option Strategy: Put Credit Spread

Traders sell a put option near the money and buy another at a lower strike. This strategy generates a credit, while limiting potential losses if prices decline.

Learn more

Bullish Option Strategy: Call Spread

Traders buy a call option near the money and sell another at a higher strike. This strategy can leverage a price increase with limited capital at risk.

Learn more

Insights AI filters through the noise to uncover meaningful data that natural-born traders can use to find new trading opportunities. Our AI model distills complex market news and data into accessible, actionable intelligence. Stay informed of market moves with curated trading intelligence and platform tips delivered directly to you.

Get connected

Market Insights, Insights AI, and all related pages and content are hosted by TradeStation Group, Inc.

The symbols selected include stocks that meet a specific set of criteria: the 50 most active stocks based on 21-day options volume. ETFs and meme stocks are not included.

This Content was created in whole or in part using Generative Artificial Intelligence (AI). While efforts have been made to ensure accuracy, the Content is generated autonomously by AI algorithms and it may contain errors or inaccuracies. Users are advised to critically evaluate the information presented.

This Content is for educational and informational purposes only. Any symbols or trading strategies discussed are for demonstration purposes only and are not research or recommendations.

TradeStation Group, Inc. (“TradeStation”) pays third parties for the data and other information included on this page (the “Content”). The Content is derived from news and other information feeds provided by Accretive Capital LLC d/b/a Benzinga (“Benzinga”) and market activity. Benzinga is not affiliated with TradeStation. TradeStation makes the Content available for informational purposes only. The Content should not be considered an offer or solicitation tobuy, sell, or hold any investment/security. The Content is believed to be from reliable sources; however, TradeStation does not verify all of the information included in the Content for accuracy or completeness. TradeStation does not endorse any third-party content, and any views or opinions expressed in the Content do not necessarily represent the views and opinions of TradeStation. Any goods or services offered by Benzinga are not sponsored, endorsed, sold, or promoted by TradeStation, and TradeStation makes no representation regarding any such goods or services.

TradeStation does not endorse or adopt the Content, and makes no guarantees that the Content is accurate, complete, or timely. TradeStation assumes no responsibility for the accuracy, completeness, updates, changes, or timeliness of the Content. TradeStation does not provide investment, tax or legal advice. Any recommendation, opinion or advice regarding securities or markets contained in the Content does not reflect the views of TradeStation. TradeStation assumes no responsibility for any fact, recommendation, opinion or advice contained in the Content and expressly disclaims any responsibility for any decisions based upon any such Content.

Any decisions you may make to buy, sell or hold a security or other investment based on the Content or other third-party information will be entirely your own and not in any way deemed to be endorsed, influenced by or attributed to TradeStation. It is understood that, without exception, any order based on the Content that is placed with TradeStation for execution should be considered by you to be an unrecommended and unsolicited order. TradeStation will treat all such orders as unsolicited.

*Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com/DisclosureOptions. Visit www.TradeStation.com/Pricing for full detailson the costs and fees associated with options.

Insights AI

Why is Hims & Hers Health Inc stock outperforming the market?